Evaluation of the Next Generation WATCHMAN LAA Closure Technology in Non-Valvular AF Patients (EVOLVE) "EVOLVE"

Completed

Phase N/A Results N/A

Eligibility Criteria

Key

Inclusion Criteria

- Paroxysmal, persistent, or permanent non-valvular atrial fibrillation
- Eligible for long-term Warfarin therapy;
- Eligible to come off Warfarin therapy if the LAA is sealed
- Calculated CHADS2 score of 1 or greater
Key

Exclusion Criteria

- New York Heart Association Class IV Congestive Heart Failure
- Recent MI (within 3 months)
- ASD and/or atrial septal repair or closure device
- Resting heart rate >110 bpm
- Has an implanted mechanical valve prosthesis
- Left atrial appendage is obliterated
- Has undergone heart transplantation
- Has symptomatic carotid disease
- Contraindicated for aspirin
- LVEF < 30%
- Cardiac Tumor